Skip to main content

Table 3 Comparison of α6 integrin and uPAR expression and clinicopathological findings

From: Interleukin-1α enhances the aggressive behavior of pancreatic cancer cells by regulating the α6β1-integrin and urokinase plasminogen activator receptor expression

   Strong co-expression both of α6 integrin and uPAR ap value
   Yes (n = 16) No (n = 26) 0.011
Gender Male/Female 11/5 16/10 N.S.
Age (year)   64.4 ± 8.6 64.3 ± 9.5 N.S.
TNM stage I/II/III/IV 2/1/6/7 7/4/12/3 N.S.
Location H/B, T 12/4 20/6 N.S.
Liver metastasis Yes/No 7/9 3/23 0.019
Lymph node matastasis Yes/No 13/3 13/13 0.045
Cancer cell differentiation P/Muc/W/Mod 1/0/4/11 2/3/13/8 N.S.
Retroperitoneal invasion Yes/No 14/2 15/11 0.045
Intrapancreatic nerve invasion Yes/No 14/2 17/9 N.S.
Lymphatic system invasion Yes/No 15/1 20/6 N.S.
Venous system invasion Yes/No 15/1 20/6 N.S.
  1. uPAR, urokinase plasminogen activator receptor; H, head of pancreas; B, body of pancreas; T, tail of pancreas; P, papillary adenocarcinoma; Muc, mucinous carcinoma; W, well-differentiated adenocarcinoma; Mod, moderatery-differentiated adenocarcinoma. The pT, pN, and pM categories were determined according to the TNM classification [19]. The ap-values were obtained using the Mann-Whiteny U test. Values of age are given mean ± s.d. N.S., no significant.